Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Open accessThe DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 89 of the 278 sources its claims cite were checked for support.
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.
Overview
CoChat Summary
TL;DR
This overview applies Chouinard and Chouinard’s diagnostic criteria to withdrawal after decrease, discontinuation, or switch of psychotropic medications, distinguishing new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. It concludes that all reviewed drug classes may induce withdrawal and rebound even with slow tapering, but SSRIs, SNRIs, and antipsychotics are consistently associated with persistent post-withdrawal disorders and potentially high severity, whereas benzodiazepine discontinuation distress appears short-lived.
Key findings
- Withdrawal reactions can occur after abrupt discontinuation or gradual tapering; prevalence was reported as 54% among adults with serious mental illness, and antidepressant withdrawal incidence ranged from 27 to 86% (weighted average 56%). New withdrawal symptoms peak at 36–96 h, last up to 6 weeks, and are usually reversible; rebound symptoms return original symptoms at greater intensity; persistent post-withdrawal disorders last >6 weeks and are potentially irreversible.
- SSRIs, SNRIs, and antipsychotics were consistently associated with persistent post-withdrawal disorders and increased severity, including altered clinical course. Venlafaxine withdrawal rates ranged from 23 to 78%, and levomilnacipran from 9 to 10%. Antipsychotic supersensitivity psychosis prevalence was reported as 65% in a long-acting injectable risperidone study, 26.5% in a retrospective aripiprazole-switch study, and 72% in treatment-resistant schizophrenia patients treated with second-generation antipsychotics.
- Benzodiazepine new withdrawal symptoms are generally mild, transient, and subside within 2–4 weeks; 75% of patients withdrawn after long-term benzodiazepine use developed new withdrawal symptoms regardless of rapid or slow elimination. Rebound anxiety occurred in 5 of 7 (71.4%) bromazepam-treated patients versus 2 of 7 (28.6%) diazepam-treated patients. Persistent post-withdrawal disorders after long-term benzodiazepine use are described, but the literature is “hardly existent.”
- Ketamine and probably its derivatives may be classified as high risk for dependence and addiction; new withdrawal symptoms typically begin within 24 h, last approximately 3 days, and may persist for 2 weeks. Lithium withdrawal evidence is weak and ambiguous, and data on mood stabilizers are limited.
Methods
- Overview/review of the literature; MEDLINE was searched from inception to January 2020, with manual searching of reference lists and relevant reviews. Search terms combined “discontinuation/withdrawal” with drug-class terms (benzodiazepine, Z-drug, antidepressant, ketamine/esketamine, antipsychotic/neuroleptic, lithium, mood stabilizer).
- Eligible articles were English, peer-reviewed papers reporting data on adult subjects who decreased, discontinued, or switched psychotropic medications. Titles and abstracts were screened by 1 reviewer; potentially relevant full reports were independently assessed by 2 reviewers to consensus.
- Withdrawal symptoms were categorized using a previously used antidepressant discontinuation categorization (general, cardiovascular, gastrointestinal, genitourinary, sensory-related, neuromuscular, sexual, and central nervous system symptoms) and classified according to Chouinard and Chouinard’s criteria for new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders.
Limitations
- Stated: evidence for lithium withdrawal is weak and ambiguous; literature on persistent post-withdrawal disorders after long-term benzodiazepine use is hardly existent, and no studies were found on managing benzodiazepine persistent post-withdrawal disorders. No persistent post-withdrawal data are published for Z-drugs, and data are limited for newer antidepressants, carbamazepine, valproate, and lamotrigine; no rebound or persistent post-withdrawal data are available for mood stabilizers.
- Stated: proposed management strategies for SSRI/SNRI withdrawal—including hyperbolically decreasing dose patterns, multistep dose reduction, and Fava and Belaise’s pharmacological/non-pharmacological strategies—need testing in randomized controlled trials. One group CBT trial found only 37% (n = 26) discontinued antidepressants and 28% (n = 20) discontinued without recurrence, though timing and sample vulnerability may have contributed.
- Evident: this is a narrative overview rather than a systematic review or meta-analysis; no formal quality appraisal or risk-of-bias assessment is described, title/abstract screening was done by one reviewer, and conclusions often rely on case reports, online reports, and limited controlled data. The authors also note a lag phase between drug marketing and description of withdrawal symptoms, which limits certainty for newer agents.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Valid · 35 Not valid · 86 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This was confirmed by other studies [53-59].”
What the sources say
- Not checked — no full text of the sourcecites [53] matched to “Quazepam and flurazepam: Long-term use and extended withdrawal” (1982) source
- Not checked — no full text of the sourcecites [54] matched to “Lorazepam: Effects on Sleep and Withdrawal Phenomena” (2008) source
- Not checked — no full text of the sourcecites [55] matched to “Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines” (1991) source
- Not checked — no full text of the sourcecites [56] matched to “Effectiveness of Temazepam with Short‐, Intermediate‐, and Long‐Term Use: Sleep Laboratory Evaluation” (1978) source
- Disputedcites [57] matched to “HYPNOTIC EFFICACY OF TEMAZEPAM: A LONG‐TERM SLEEP LABORATORY EVALUATION” (1979) sourceExperimental — accuracy not yet measured
The Discussion (page not specified in our copy) says the study found no evidence of rebound insomnia after abrupt withdrawal of temazepam. Although this paper evaluated a short-term protocol, it does not confirm the attributed finding; it reports the opposite for the benzodiazepine it studied. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [58] matched to “Flurazepam for Short‐Term Treatment of Complaints of Insomnia” (1982) source
- Disputedcites [59] matched to “Temazepam's efficacy in patients with sleep onset insomnia.” (1984) sourceExperimental — accuracy not yet measured
The Design section describes nine nights of temazepam followed by three placebo recovery nights. Rather than confirming rebound insomnia after cessation, the Discussion (p. 695) says there was “no consistent disruption of sleep” and that mean sleep time during recovery was similar to baseline, although four of 12 patients had some disturbed recovery nights. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Recently, it has been described the case of a patient in which PSSD symptoms were part of a broader syndrome which was diagnosed as persistent post-withdrawal disorder [129].”
What the sources say
- Could not verifycites [129] matched to “Gender differences in subjective discontinuation symptoms associated with ketamine use” (2014) sourceExperimental — accuracy not yet measured
The Discussion > Discontinuation symptoms passage concerns ketamine withdrawal, not PSSD or a diagnosis of persistent post-withdrawal disorder. Searches for those terms and for a patient case found no passage in our copy addressing the claimed case. (LLM, conf=0.76)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“One study found acute dystonia as new withdrawal symptom resulting from abrupt discontinuation of bupropion [105].”
What the sources say
- Could not verifycites [105] matched to “SSRI and SNRI withdrawal symptoms reported on an internet forum” (2018) sourceExperimental — accuracy not yet measured
The Method and Results (pages unavailable) describe withdrawal reports involving SSRIs and SNRIs, not bupropion. A search for bupropion, acute dystonia, and movement disorders found no passage addressing the claimed symptom after abrupt bupropion discontinuation. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The evidence for withdrawal after lithium decrease or discontinuation is weak and ambiguous.”
What the sources say
- Could not verifycites [173] matched to “Iatrogenic Comorbidity in Childhood and Adolescence: New Insights from the Use of Antidepressant Drugs” (2014) sourceExperimental — accuracy not yet measured
Section 2.1 mentions cognitive impairments with lithium and reports withdrawal reactions across psychotropic drugs, but does not assess the evidence for withdrawal specifically after lithium dose reduction or discontinuation. A search for lithium found no passage characterizing that evidence as weak or ambiguous; page numbers were unavailable in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
What the sources say
- Could not verifycites [21] matched to “Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review” (2018) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [22] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [150] matched to “Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients” (2012) source
- Not checked — no full text of the sourcecites [151] matched to “Reply to Article by Margolese and Associates on Tolerance and Rebound During Maintenance With Quetiapine” (2004) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
91 more claims · 25 with their cited sources checked
Create a free account to see all 177 claims and every source verdict.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 56
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longer-term BZD use and use of high-dose, rapid-acting BZDs increase the risk of protracted withdrawal”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with other psychotropics, the potential for antidepressant PWS is embedded in pharmacodynamic adaptations and possibly irreversible neurophysiological alterations following prolonged drug exposure.19,20,31”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Untreated symptoms may be mild and resolve spontaneously in 1–3 weeks; in other cases they may persist for months or even years,40–45 leading to what has been defined as persistent post-withdrawal disorder.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Reed, G. M., First, M. B., Kogan, C. S., Hyman, S. E., Gureje, O., Gaebel, W., Maj, M., Stein, D. J., Maercker, A., Tyrer, P., et al. (2019) · World Psychiatry · doi:10.1002/wps.20611 · Cited by 765
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Cited by
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 95
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Prodromal Symptoms in Depression: A Systematic Review
Benasi, G., Fava, G. A., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517953 · Cited by 73
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Benzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 86
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“However, as was the case with SSRIs and SNRIs, post-approval real-world data will be essential to confirm the safety profiles of the drugs and document potential adverse events or withdrawal syndrome that may arise with long-term use [148, 149].”
BackgroundBreedvelt, J. J. F., Warren, F. C., Segal, Z., Kuyken, W., & Bockting, C. L. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0823 · Cited by 68
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63
Self-citationGastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
“Although the hypothesis that antidepressants may carry a potential risk for withdrawal syndrome that is similar to addictive drugs is not new [45], we are not aware of any direct comparison between antidepressants and opioids.”
BackgroundYang, S. Q., Zhou, Y., Yang, S. T., Mao, X., Chen, L., Bai, Z.-H., Ping, A. Q., Xu, S. Y., Li, Q. W., Gao, K., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.007 · Cited by 66
Clozapine discontinuation withdrawal symptoms in schizophrenia
Blackman, G., & Oloyede, E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032053 · Cited by 62
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
“Symptoms are generally mild and self-limiting [48, 73].”
BackgroundInfluentialThe Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507227 · Cited by 48
Self-citationGroot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320932452 · Cited by 49
Wang, J., & Cosci, F. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000516031 · Cited by 47
Self-citationQiu, X., Chen, C., Shi, Y., Chen, K., Li, M., Xu, H., Wu, X., Takai, Y., Shimasaki, Y., & Oshima, Y. (2022) · Aquatic Toxicology · doi:10.1016/j.aquatox.2022.106129 · Cited by 46
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“78,130,132 Protracted withdrawal symptoms can adversely affect patients’ relationships, family life, careers, and mental health.”
Swainson, J., Klassen, L. J., Brennan, S., Chokka, P. R., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00897-2 · Cited by 54
“However, a recent review cautions ketamine withdrawal symptoms that include craving, palpitations, tiredness, low appetite, low mood, chills, autonomic arousal, lacrimation, restlessness, paranoia, anxiety, hallucinations, and delusions beginning 24 h post-ketamine, and lasting up to 2 weeks [50].”
BackgroundPinkhasov, A., Xiong, G. L., Bourgeois, J. A., Heinrich, T. W., Huang, H., Coriolan, S., Annamalai, A., Mangal, J. P., Frankel, S. A., Lang, M. C., et al. (2021) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2021.110654 · Cited by 58
The emerging role of euthymia in psychotherapy research and practice
Guidi, J., & Fava, G. A. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101941 · Cited by 40
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38
“These findings and the results of our earlier reports [9, 10] conflict with some of the literature [11].”
ResultStrumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 48
“Importantly, the full clinical response to classic antidepressants is generally observed after at least two weeks, and the unfavorable side-effect profile frequently results in premature or abrupt discontinuations [12,13].”
BackgroundFava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520251 · Cited by 46
Alsheikh, M. Y. (2021) · Archives of Pharmacy Practice · doi:10.51847/ioicfujpnm · Cited by 34
“However, relapse phenomenon is when patients experience returns of signs and symptoms of the original disorder after a remission due to natural causes or cessation of therapy, while recurrence phenomenon is when patients experience a new episode of the original disorder [7, 8, 23, 25].”
BackgroundInfluentialPsilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
Barbuti, M., Menculini, G., Verdolini, N., Pacchiarotti, I., Kotzalidis, G. D., Tortorella, A. A. V., Vieta, E., & Perugi, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.013 · Cited by 40
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 35
Raballo, A., Poletti, M., & Preti, A. (2022) · Psychological Medicine · doi:10.1017/s0033291722001428 · Cited by 42
“There is also robust evidence for a withdrawal syndrome after long-term use of ADs (Fava, Gatti, Belaise, Guidi, & Offidani, 2015, 2018), which sometimes may become persistent and difficult to treat (Cosci & Chouinard, 2020).”
BackgroundChiappini, S., Vickers‐Smith, R., Guirguis, A., Corkery, J., Martinotti, G., & Schifano, F. (2022) · Pharmaceuticals · doi:10.3390/ph15050565 · Cited by 40
“Indeed, when tapering down a therapeutic dosage of AD, symptoms most typically are both mild/go untreated and resolve spontaneously [81,83].”
BackgroundHorowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Voderholzer, U., Barton, B. B., Favreau, M., Zisler, E. M., Rief, W., Wilhelm, M., & Schramm, E. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1415905 · Cited by 54
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00014-1 · Cited by 35
Rink, L., Adams, A., Braun, C., Bschor, T., Kuhr, K., & Baethge, C. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520554 · Cited by 36
Saavedra, P. A. E., Galato, D., Silva, C. M. D. S., da Silva, I. C. R., & da Silva, E. V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1028233 · Cited by 34
Read, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30
Staging of unipolar depression: systematic review and discussion of clinical implications
Cosci, F., & Fava, G. A. (2022) · Psychological Medicine · doi:10.1017/s0033291722001507 · Cited by 28
“…started again after a drug-free period; new withdrawal or rebound syndromes after tapering, switching, and/or discontinuation of an antidepressant (Cosci & Chouinard, 2020); persistent post-withdrawal disorder after tapering, switching, and/or discontinuation of an antidepressant (Cosci &…”
BackgroundSelf-citationAntidepressant discontinuation syndrome: A state-of-the-art clinical review
Fornaro, M., Cattaneo, C. I., Berardis, D. D., Ressico, F. V., Martinotti, G., & Vieta, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.005 · Cited by 37
Han, Z., Wang, L., Zhu, H., Tu, Y., He, P., & Li, B. (2024) · Food Research International · doi:10.1016/j.foodres.2024.115191 · Cited by 32
Robberegt, S. J., Brouwer, M. E., Kooiman, B., Stikkelbroek, Y. A. J., Nauta, M. H., & Bockting, C. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.04.014 · Cited by 40
Davies, J., Cooper, R. E., Moncrieff, J., Montagu, L., Rae, T. C., & Parhi, M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107143 · Cited by 30
Costa, M. D. A., Gonçalves, F. G., Tatton-Ramos, T., Fonseca, N. K. D. O. D., Schwinn, J. K., Alves, S. G., Salum, G. A., & Manfro, G. G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000511880 · Cited by 26
Watts, M., Murphy, E., Keogh, B., Downes, C., Doyle, L., & Higgins, A. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12894 · Cited by 25
Cosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Self-citationClinimetric Perspectives in Clinical Psychology and Psychiatry
Cosci, F. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517028 · Cited by 30
Self-citationThe need for antidepressant withdrawal support services: Recommendations from 708 patients
Read, J., Lewis, S., Horowitz, M., & Moncrieff, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115303 · Cited by 24
Outcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22
“We cannot assume the sample is representative for the entire population of people who want to taper their antidepressant medication, even though (1) attrition analysis suggested a degree of generalisability as responders and non-responders were very similar in terms of demographics, type of medication, risk factors an…”
BackgroundMethodAdverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · doi:10.48350/165893 · Cited by 24
Tapering antipsychotic medication: practical considerations
Horowitz, M. A., Moncrieff, J., de Haan, L., Bogers, J. P. A. M., Gangadin, S. S., Kikkert, M., Veling, W., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721003299 · Cited by 30
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Self-citationCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
“Withdrawal symptoms can include anxiety, agitation, depressed mood, sudden changes in mood, muscle spasms, diarrhoea, dizziness, insomnia, nausea, brain ‘zaps’, flu-like symptoms, and suicidality [13, 14].”
BackgroundWiesinger, T., Kremer, S., Bschor, T., & Baethge, C. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13541 · Cited by 30
Horowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 23
Montano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 31
“● Serotonin antagonist and reuptake inhibitor; combined effect on serotonin reuptake pumps and 5HT2A/2C receptors via both receptor agonist and antagonist activities [44] ● Trazodone ● Nefazodone ● Comorbid insomnia or GAD [44,45] ● Sedation, nausea, priapism (rare), orthostatic hypotension [8] ● Reduced risk of sexua…”
BackgroundConceptual and Clinical Innovations of Well-being Therapy
Guidi, J., & Fava, G. A. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00101-1 · Cited by 30
Sørensen, A., Jørgensen, K. J., & Munkholm, K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.011 · Cited by 25
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Chiappini, S., Sampogna, G., Ventriglio, A., Menculini, G., Ricci, V., Pettorruso, M., Volpe, U., & Martinotti, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2470973 · Cited by 24
Jeong, H., Yim, H. W., Lee, S., Potenza, M. N., & Kim, N. J. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000529753 · Cited by 25
Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Sun, C.-F., Pola, A. S., Su, K., Lin, B. Y., Kablinger, A. S., & Trestman, R. L. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100270 · Cited by 19
“Additionally, both chronic BZD use and BZD withdrawal can cause or intensify depression (Ashton, 1991) (Cosci and Chouinard, 2020).”
BackgroundControversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder
Smith, K. E., Epstein, D. H., & Weiss, S. T. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01524-1 · Cited by 18
“By those two criteria, an SUD diagnosis would apply to many people who take prescribed psychiatric medications, because such medications often induce tolerance on initial titration and cannot be abruptly discontinued without withdrawal symptoms [4].”
BackgroundPrescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?
Cosci, F., & Fava, G. A. (2021) · Biomedicine Hub · doi:10.1159/000519656 · Cited by 19
Self-citationSchnyder, U. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000527462 · Cited by 19
Discontinuing antidepressants: Pearls and pitfalls
Zwiebel, S. J., & Viguera, A. C. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21020 · Cited by 20
Tachibana, M., Kanahara, N., Oda, Y., Hasegawa, T., Kimura, A., & Iyo, M. (2024) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10946 · Cited by 17
Risk factors for early recurrence after discontinuing lithium in bipolar disorder
Baldessarini, R. J., Pinna, M., Contu, M., Vázquez, G. H., & Tondo, L. (2022) · Bipolar Disorders · doi:10.1111/bdi.13206 · Cited by 19
Benzodiazepine high‐doses: The need for an accurate definition
Cloos, J. M., Cow, C. Y. S. L., & Bocquet, V. (2021) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1888 · Cited by 21
“…rebound symptoms, and persistent postwithdrawal disorders may however occur in several drug classes after decrease, discontinuation, or switch of psychotropic medications (Cosci & Chouinard, 2020), and some patients develop a tolerance to certain substances and progressively increased dosages.”
BackgroundCosci, F., Romanazzo, S., Mansueto, G., Rontani, P., Levitan, M. N., Halkjœr-Lassen, R. D., Quagliato, L. A., Nakamura, T., Uematsu, K., Nardi, A. E., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001491 · Cited by 16
Self-citationKimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 17
Vaismoradi, M., Mardani, A., Lillo‐Crespo, M., Logan, P., & Sak‐Dankosky, N. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241289205 · Cited by 18
“75,76 Nurses can facilitate smooth medication discontinuation by monitoring patients, managing symptoms, providing reassur-ance and ensuring prompt communication with the healthcare team and patients.”
BackgroundWallis, K. A., Donald, M., Horowitz, M. A., Moncrieff, J., Ware, R. S., Byrnes, J., Thrift, K., Cleetus, M., Panahi, I., Zwar, N. A., et al. (2023) · Trials · doi:10.1186/s13063-023-07646-w · Cited by 18
“Withdrawal symptoms include anxiety, low mood, dizziness, ‘brain fog’, irritability, headache, and insomnia, which can last for weeks or months with severity likely proportional to duration of use [14–17].”
BackgroundIs there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 17
“Moreover, discontinuing these medications even temporarily can precipitate withdrawal symptoms (Cosci and Chouinard 2020; Fornaro et al. 2023).”
Cosci, F. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000535262 · Cited by 12
Self-citationOkada, Y., & Akazawa, M. (2021) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-021-02147-0 · Cited by 12
Tapering antidepressants: why do tens of thousands turn to Facebook groups for support?
White, E. (2021) · British Journal of General Practice · doi:10.3399/bjgp21x716309 · Cited by 12
Iatrogenic Side Effects of Pain Therapies
Gharibo, C. G., Drewes, A. M., Breve, F., Rekatsina, M., Tamayo, M. A. N., Varrassi, G., & Paladini, A. (2023) · Cureus · doi:10.7759/cureus.44583 · Cited by 16
“While tapering plans have been published, tapering is often highly individual as some patients may require slower tapers or more time “plateauing” at specific doses than others [83].”
BackgroundSSRI withdrawal syndrome in children and adolescents: a narrative literature review
Khan, Y. S., Khoodoruth, M. A. S., Albobali, Y., & Haddad, P. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2224557 · Cited by 12
“Based on this limited data and extrapolating from adult literature, it can be assumed that six pharmacological strategies could be adopted when a child or young person experiences SSRI withdrawal symptoms [36].”
BackgroundCosci, F., Chouinard, V.-A., & Chouinard, G. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540031 · Cited by 11
Self-citationLaurent, N. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1331181 · Cited by 11
Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach
Pallanti, S., Zohar, J., Kasper, S. F., Möller, H., & Hollander, E. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.11.042 · Cited by 15
Wisłowska-Stanek, A., Jarkiewicz, M., & Mirowska-Guzel, D. M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00689-z · Cited by 18
“They typically begin within 24 h of discontinuation and last approximately 3 days, although in some cases they may persist for 2 weeks [17].”
InfluentialCarroll, A., Bayes, A. J., Montebello, M. E., Brett, J., Arunogiri, S., Saunders, J. B., & Loo, C. K. A. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241242315 · Cited by 10
“In human studies, a withdrawal syndrome from chronic exposure to ketamine has been described (Cosci and Chouinard, 2020; Roxas et al., 2021).”
Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06554-4 · Cited by 10
“(Brandt et al. 2022, 2020; Cosci and Chouinard 2020) It could be argued that those receptors might undergo a similar upregulation process as seen in dopaminergic receptors resulting in receptor supersensitivity and subsequent withdrawal symptoms.”
Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity
Starčević, V. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524772 · Cited by 12
Nardi, A. E., & Quagliato, L. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524730 · Cited by 14
Predictors of successful discontinuation of antipsychotics and antidepressants
Lincoln, T. M., Sommer, D., Quazzola, M., Witzgall, T., & Schlier, B. (2021) · Psychological Medicine · doi:10.1017/s0033291721005146 · Cited by 13
“However, the subsample discontinuing firstgeneration AP was small and previous research provides limited support for the claim of less withdrawal problems with secondgeneration AP (Cosci & Chouinard, 2020), necessitating replication before further interpreting this finding.”
BackgroundMethodResultInfluentialPeng, L., Lawrence, D. M., & Levander, X. A. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000869 · Cited by 11
Meißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04941-3 · Cited by 11
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2024) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 16
“The incidence and severity of withdrawal symptoms depend on how the dose is tapered [8–11], and symptoms can occur even following very small dose reductions [11,12].”
InfluentialCohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
King, S. R., Allan, M., & Lindsey, L. (2022) · Psychosis · doi:10.1080/17522439.2022.2141841 · Cited by 8
“Irrespective, it is essential for all practitioners to promote harm reduction (Hall et al., 2007) and be aware of the continual struggle with the emotional and physical effects resulting from antipsychotic use and withdrawal (Cosci & Chouinard, 2020).”
BackgroundHelping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 11
“This is also likely to be explained by the underlying nature of the condition to some extent, but it may also re fl ect the consequences of antipsychotic withdrawal, analogous to the protracted withdrawal states that have been reported following benzodiazepine and antidepressant withdrawal 84 – 87 .”
Metadata
- Authors
- Cosci, F., & Chouinard, G.
- Affiliations
- Maastricht University (NL)
- McGill University (CA)
- ORCID
- Cosci, Fiammetta
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 283-306
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3014423675
- Cited by
- 265
- References
- 219
- Citations by year
- 2026: 35 · 2025: 34 · 2024: 53 · 2023: 45 · 2022: 37 · 2021: 45 · 2020: 16
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- drug discontinuation, benzodiazepines, antidepressants, ketamine, antipsychotic drugs, lithium, mood stabilizers, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, quetiapine, drug addiction, children and adolescents
- MeSH terms
- Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.